Company intelligence / Profile preview

Fragment BioTech

Ownership: Private
Development stage: Other

Overview

Fragment BioTech has developed an innovative rapid biosensing platform capable of detecting biomarkers in saliva and other liquid biopsies. The technology is benchmarked against current gold standards, aiming to improve the speed, accessibility, and precision of biomarker-based screening for cancers, infectious diseases, and environmental contaminants. The company has received multiple innovation awards for its wearable/portable sensing technologies but does not appear to have therapeutics or drugs in clinical trials.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: Diagnostic deviceBiosensor technology
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Fragment BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fragment BioTech.

Explore the full profile